Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore Bianchi, Livio Trusolino, Cosimo Martino et al. · The Lancet Oncology · 2016
Cited by 1,016 works. doi:10.1016/s1470-2045(16)00150-9 Open-access PDF
Authors
- Andrea Sartore Bianchi
- Livio Trusolino
- Cosimo Martino
- Katia Bruna Bencardino
- Sara Lonardi
- Francesca Bergamo
- Vittorina Zagonel
- Francesco Leone
- Ilaria Depetris
- Erika Martinelli
- Teresa Troiani
- Fortunato Ciardiello
- Patrizia Racca
- Andrea Bertotti
- Giulia Siravegna
- Valter Torri
- Alessio Amatu
- Silvia Ghezzi
- Giovanna Marrapese
- Laura Palmeri
References
- The meaning and use of the area under a receiver operating characteristic (ROC) curve.
- Comprehensive molecular characterization of human colon and rectal cancer
- Evaluating the Yield of Medical Tests
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- Cancer Genome Landscapes
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
- An introduction to recursive partitioning: Rationale, application, and characteristics of classification and regression trees, bagging, and random forests.
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer